Nos dernières publications

Rapport scientifique 2020

Télécharger le document

Articles

• Ostkamp P, Salmen A, Pignolet B, Görlich D, Andlauer TFM, Schulte-Mecklenbeck A, Gonzalez-Escamilla G, Bucciarelli F, Gennero I, Breuer J, Antony G, Schneider-Hohendorf T, Mykicki N, Bayas A, Then Bergh F, Bittner S, Hartung HP, Friese MA, Linker RA, Luessi F, Lehmann-Horn K, Mühlau M, Paul F, Stangel M, Tackenberg B, Tumani H, Warnke C, Weber F, Wildemann B, Zettl UK, Ziemann U, Müller-Myhsok B, Kümpfel T, Klotz L, Meuth SG, Zipp F, Hemmer B, Hohlfeld R, Brassat D, Gold R, Gross CC, Lukas C, Groppa S, Loser K, Wiendl H, Schwab N; German Competence Network Multiple Sclerosis (KKNMS) and the BIONAT Network. Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity. Proc Natl Acad Sci U S A. 2021 Jan 5;118(1):e2018457118. doi: 10.1073/pnas.2018457118.
  https://pubmed.ncbi.nlm.nih.gov/33376202/

• Roos I, Leray E, Frascoli F, Casey R, Brown JWL, Horakova D, Havrdova EK, Debouverie M, Trojano M, Patti F, Izquierdo G, Eichau S, Edan G, Prat A, Girard M, Duquette P, Onofrj M, Lugaresi A, Grammond P, Ciron J, Ruet A, Ozakbas S, De Seze J, Louapre C, Zephir H, Sá MJ, Sola P, Ferraro D, Labauge P, Defer G, Bergamaschi R, Lebrun-Frenay C, Boz C, Cartechini E, Moreau T, Laplaud D, Lechner-Scott J, Grand’Maison F, Gerlach O, Terzi M, Granella F, Alroughani R, Iuliano G, Van Pesch V, Van Wijmeersch B, Spitaleri D, Soysal A, Berger E, Prevost J, Aguera-Morales E, McCombe P, Castillo Triviño T, Clavelou P, Pelletier J, Turkoglu R, Stankoff B, Gout O, Thouvenot E, Heinzlef O, Sidhom Y, Gouider R, Csepany T, Bourre B, Al Khedr A, Casez O, Cabre P, Montcuquet A, Wahab A, Camdessanche JP, Maurousset A, Patry I, Hankiewicz K, Pottier C, Maubeuge N, Labeyrie C, Nifle C, Coles A, Malpas CB, Vukusic S, Butzkueven H, Kalincik T. Determinants of therapeutic lag in multiple sclerosis. Mult Scler. 2021 Jan 11:1352458520981300. doi: 10.1177/1352458520981300. Online ahead of print. PMID: 33423618
  https://pubmed.ncbi.nlm.nih.gov/33423618/

• Rollot F, Casey R, Leray E, Debouverie M, Edan G, Wiertlewski S, Vukusic S, Laplaud DA. Cumulative effects of therapies on disability in relapsing multiple sclerosis. .Mult Scler. 2021 Jan 6:1352458520980366. doi: 10.1177/1352458520980366. Online ahead of print. PMID: 33403937
  https://pubmed.ncbi.nlm.nih.gov/33403937/

• Deschamps R, Pique J, Ayrignac X, Collongues N et al. The long-term outcome of MOGAD: an observational national cohort study of 61 patients. Eur J Neurol. 2021 Feb 2. doi: 10.1111/ene.14746.
  https://pubmed.ncbi.nlm.nih.gov/33528851/

• Kaminsky AL, Omorou AY, Soudant M, Pittion-Vouyovitch S, Michaud M, Anxionnat R, Guillemin F, Debouverie M, Mathey G. Discontinuation of disease-modifying treatments for multiple sclerosis in patients aged over 50 with disease Inactivity. J Neurol. 2020 Dec;267(12):3518-3527. doi: 10.1007/s00415-020-10029-9. Epub 2020 Jul 2. PMID: 32617659.
  https://pubmed.ncbi.nlm.nih.gov/32617659/

• Vukusic S, Casey R, Rollot F, Brochet B, Pelletier J, Laplaud DA, De Sèze J, Cotton F, Moreau T, Stankoff B, Fontaine B, Guillemin F, Debouverie M, Clanet M. Observatoire Français de la Sclérose en Plaques (OFSEP): A unique multimodal nationwide MS registry in France. Mult Scler. 2020 Jan;26(1):118-122
  https://pubmed.ncbi.nlm.nih.gov/30541380/

• Brisset JC, Kremer S, Hannoun S, Bonneville F, Durand-Dubief F, Tourdias T, Barillot C, Guttmann C, Vukusic S, Dousset V, Cotton F; Collaborators. New OFSEP recommendations for MRI assessment of multiple sclerosis patients: Special consideration for gadolinium deposition and frequent acquisitions. J Neuroradiol. 2020 Jun;47(4):250-258
  https://pubmed.ncbi.nlm.nih.gov/32014494/

• Brissart H, Omorou AY, Forthoffer N, Berger E, Moreau T, De Seze J, Morele E, Debouverie M. Memory improvement in multiple sclerosis after an extensive cognitive rehabilitation program in groups with a multicenter double-blind randomized trial. Clin Rehabil. 2020 Jun;34(6):754-763
  https://pubmed.ncbi.nlm.nih.gov/32475261/

• Cohen M, Mondot L, Bucciarelli F, Pignolet B, Laplaud DA, Wiertlewski S, Brochet B, Ruet A, Defer G, Derache N, Vermersch P, Zephir H, Debouverie M, Mathey G, Berger E, Cappé C, Labauge P, Carra C, De Seze J, Bigaut K, Brassat D, Lebrun-Frenay. BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS. Mult Scler. 2020 Oct 30:1352458520969145. doi: 10.1177/1352458520969145. Online ahead of print.PMID: 33124504
  https://pubmed.ncbi.nlm.nih.gov/33124504/

• Roos I, Leray E, Frascoli F, Casey R, Brown JWL, Horakova D, Havrdova EK, Trojano M, Patti F, Izquierdo G, Eichau S, Onofrj M, Lugaresi A, Prat A, Girard M, Grammond P, Sola P, Ferraro D, Ozakbas S, Bergamaschi R, Sá MJ, Cartechini E, Boz C, Granella F, Hupperts R, Terzi M, Lechner-Scott J, Spitaleri D, Van Pesch V, Soysal A, Olascoaga J, Prevost J, Aguera-Morales E, Slee M, Csepany T, Turkoglu R, Sidhom Y, Gouider R, Van Wijmeersch B, McCombe P, Macdonell R, Coles A, Malpas CB, Butzkueven H, Vukusic S, Kalincik T; MSBase; OFSEP investigators. Delay from treatment start to full effect of immunotherapies for multiple sclerosis. 2020 Sep 1;143(9):2742-2756.
  https://pubmed.ncbi.nlm.nih.gov/32947619/